Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer

Elevated, tumor-derived extracellular vesicle (tdEV) and circulating tumor cell (CTC) loads in metastatic cancer are associated with poor clinical outcome. Herein, we investigate whether endothelium-derived extracellular vesicles (edEVs) can be detected in the blood of metastatic colorectal cancer (...

Full description

Bibliographic Details
Main Authors:	Afroditi Nanou, Linda Mol, Frank A. W. Coumans, Miriam Koopman, Cornelis J. A. Punt, Leon W. M. M. Terstappen
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Cells
Subjects:	metastatic colorectal cancer (mCRC) endothelium-derived extracellular vesicles (edEVs) circulating endothelial cells (CECs) CellSearch ACCEPT CAIRO2
Online Access:	https://www.mdpi.com/2073-4409/9/12/2688

Similar Items

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles
by: Afroditi Nanou, et al.
Published: (2018-10-01)

Leukocyte-Derived Extracellular Vesicles in Blood with and without EpCAM Enrichment
by: Afroditi Nanou, et al.
Published: (2019-08-01)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
by: Afroditi Nanou, et al.
Published: (2020-08-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

Extracellular vesicles: how they interact with endothelium, potentially contributing to metastatic cancer cell implants
by: Murray M. Bern
Published: (2017-09-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer
by: Hugo Levillain, et al.
Published: (2020-12-01)

Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer
by: Francesca Belardinilli, et al.
Published: (2020-05-01)

Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital
by: Meiqin Yuan, et al.
Published: (2021-05-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer
by: Bendell, J.C, et al.
Published: (2022)

Next generation sequencing identifies ‘interactome’ signatures in relapsed and refractory metastatic colorectal cancer
by: Johnson, Benny, et al.
Published: (2017)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
by: Xia-Hong You, et al.
Published: (2019-08-01)

Identification of Cross Talk between FoxM1 and RASSF1A as a Therapeutic Target of Colon Cancer
by: Thomas G. Blanchard, et al.
Published: (2019-02-01)

Routes and mechanisms of extracellular vesicle uptake
by: Laura Ann Mulcahy, et al.
Published: (2014-08-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
by: Yuankai Shi, et al.
Published: (2019-05-01)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
by: Riccardo Giampieri, et al.
Published: (2021-09-01)

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
by: Francesca Pirini, et al.
Published: (2020-05-01)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
by: Wafik S. El-Deiry, et al.
Published: (2019-03-01)

Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
by: Wang Z, et al.
Published: (2019-01-01)

Extracellular Vesicles in Skin Wound Healing
by: Deimantė Narauskaitė, et al.
Published: (2021-08-01)

Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer
by: Céline Bouvy, et al.
Published: (2014-07-01)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
by: Yifan Xu, et al.
Published: (2018-11-01)

From Mesenchymal Stromal Cells to Engineered Extracellular Vesicles: A New Therapeutic Paradigm
by: Jancy Johnson, et al.
Published: (2021-07-01)

Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study
by: Umberto Malapelle, et al.
Published: (2020-09-01)

Quality of extracellular vesicle images by transmission electron microscopy is operator and protocol dependent
by: L. G. Rikkert, et al.
Published: (2019-12-01)

Circulating tumor cells in breast cancer
by: Geetha Pukazhendhi, et al.
Published: (2014-01-01)

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
by: Kei Muro, et al.
Published: (2020-03-01)

90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer
by: Hugo Levillain, et al.
Published: (2018-07-01)

Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer Immunotherapy and Vaccines
by: Irene Fernández-Delgado, et al.
Published: (2020-11-01)

Targeting the Endothelium to Achieve Cardioprotection
by: Nicolas Herrera-Zelada, et al.
Published: (2021-02-01)

Breast Cancer Derived Extracellular Vesicles in Bone Metastasis Induction and Their Clinical Implications as Biomarkers
by: Simona Taverna, et al.
Published: (2020-05-01)

Extracellular Vesicle Quantification and Characterization: Common Methods and Emerging Approaches
by: Thomas A. Hartjes, et al.
Published: (2019-01-01)

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
by: Alessandro Parisi, et al.
Published: (2020-05-01)

Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method
by: Anna Woestemeier, et al.
Published: (2020-03-01)

The Evolving Role of Caveolin-1: A Critical Regulator of Extracellular Vesicles
by: Kareemah Ni, et al.
Published: (2020-11-01)